Minerva
Minerva
复制标题
DOI：
10.1136/sti.2011.d1906rep
复制
发表时间：
2011-07
影响因子：
3.6
通讯作者：
K. Yoganathan;S. Danino
中科院分区：
文献类型：
--
作者：
K. Yoganathan;S. Danino
引用1。Walboomers JMM, Jacobs MV， Manos MM等。人乳头瘤病毒是世界范围内侵袭性宫颈癌的必要病因。[J]中华病毒学杂志1999；19(1):1 - 9。2. Anttila T, Saikku P, Koskela P，等。沙眼衣原体血清型与宫颈鳞状细胞癌发展的风险。《美国医学会杂志》2001;285:47e51。3. 王志强，王志强，王志强，等。沙眼衣原体感染与宫颈癌的人群前瞻性研究。中华医学杂志2002；31(1):391 - 391。4. 陈建军，陈建军，陈建军，等。人乳头瘤病毒和沙眼衣原体在原位和浸润性宫颈腺癌中的综合分析。中华妇产科杂志2009；14:391 - 391。5. Naucler P，陈海成，Persson K，等。人乳头瘤病毒和沙眼衣原体的血清患病率与宫颈癌风险：巢式病例对照研究。中国生物医学工程学报（英文版）；2009;33(2):391 - 391。6. 潘文华，李春华。宫颈衣原体感染的细胞学研究。医学与生物杂志1980；58:174。7. lostarinen T, Lehtinen M, Bjorge T，等。不同人乳头瘤病毒和沙眼衣原体感染对宫颈鳞状细胞癌风险的共同影响。[J]中华医学杂志2004；44(4):591 - 591。8. 生殖道HPV感染的免疫应答和宫颈癌的病因学。斯德哥尔摩，瑞典：卡罗林斯卡学院，2005:1e75。http://diss。kib. kiss .se/2005/91-7140-266-7/thesis.pdf（2009年10月22日访问）。9. Agrawal T, Vats V, Wallace L.宫颈树突状细胞亚群、共刺激分子、细胞因子分泌谱和β -雌二醇在沙眼衣原体感染后遗症发展中的作用。中国生物医学工程学报，2008;6(6):444。10. 李建军，李建军，李建军，等。沙眼衣原体感染与人乳头瘤病毒的持久性。国际癌症杂志2005；16(1):1 - 5。11. 李建军，李建军，李建军，等。沙眼衣原体与女性青少年中高危型人乳头瘤病毒持续存在的关系[J]中华流行病学杂志2005；32(2):668 - 668。12. 陈建军，朱旭，吴科洛，等。女性HPV生殖器感染的患病率和发病率。性学杂志2009；36:696 - 703。13. show ML, Fortenberry JD, Tu W，等。青春期妇女使用避孕套、性行为和性传播感染与生殖器人乳头瘤病毒感染持续时间的关系。中华儿科与青少年医学杂志；2006;16:391 - 391。14. Garland SM, Hernandez-Avila M, Wheeler CM，等。预防肛门生殖器疾病的人乳头瘤病毒四价疫苗。中华医学杂志，2007;35(6):391 - 391。15. FUTURE II研究小组。预防宫颈高度病变的人乳头瘤病毒四价疫苗。中华医学杂志，2007;35(6):391 - 391。16. 国际专利号wo2003 /019143 A2， wo2006 /116276 A2和wo2006 /116303 A2。http://www.wipo.int/portal/index.html.en。（2010年5月5日查阅）。17. Villa LL, Costa RLR， Petta CA等。年轻女性预防性四价人乳头瘤病毒（6、11、16和18型）L1病毒样颗粒疫苗：一项随机双盲安慰剂对照多中心II期疗效试验柳叶刀肿瘤学杂志2005；6:27 - 18。18. Mao C, Koutsky LA, Ault KA，等。人乳头瘤病毒-16疫苗预防宫颈上皮内瘤变的疗效：一项随机对照试验妇产科杂志2006；107:18 - 27。19. 李宁，王晓东，王晓东，等。人类乳头瘤病毒在全球30,848例浸润性宫颈癌中的类型分布：按地理区域、组织学类型和出版年份划分的差异中华医学杂志，2011;28(2):391 - 391。20.。回归模型和生命表。[J] .社会科学与社会科学[J]; 2008; 22(4): 391 - 391。21. Koutsky LA, Holmes KK, Critchlow CW，等。宫颈上皮内瘤变2级或3级风险与乳头瘤病毒感染的队列研究中华医学杂志（英文版）1992;327:1272 - 1280。22. Lehtinen M, Dillner J, Knekt P，等。血清学诊断为16型人乳头瘤病毒感染和随后发展为宫颈癌的风险：巢式病例对照研究[J] .中华医学杂志，1996;32(3):591 - 591。23. Schiffman M, Clifford G, Buonaguro FM。弱致癌性人乳头瘤病毒类型的分类：解决流行病学的界限。感染因子2009；4:8。
REFERENCES 1. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12e19. 2. Anttila T, Saikku P, Koskela P, et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 2001;285:47e51. 3. Wallin KL, Wiklund F, Luostarinen T, et al. A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Int J Cancer 2002;101:371e4. 4. Quint KD, de Koning MN, Geraets DT, et al. Comprehensive analysis of Human Papillomavirus and Chlamydia trachomatis in in-situ and invasive cervical adenocarcinoma. Gynecol Oncol 2009;114:390e4. 5. Naucler P, Chen H-C, Persson K, et al. Seroprevalence of human papillomavirus and Chlamydia trachomatis and cervical cancer risk: nested case-control study. J Gen Virol 2007;88:814e22. 6. Paavonen J, Purola E. Cytological findings in cervical chlamydial infection. Med Biol 1980;58:174e8. 7. Luostarinen T, Lehtinen M, Bjorge T, et al. Joint effects of different human papillomaviruses and Chlamydia trachomatis infections on risk of squamous cell carcinoma of the cervix uteri. Eur J Cancer 2004;40:1058e65. 8. Arnheim L. Immunological Responses in Genital HPV Infections and Etiology of Cervical Cancer. Stockholm, Sweden: Karolinska Institutet, 2005:1e75. http://diss. kib.ki.se/2005/91-7140-266-7/thesis.pdf (accessed 22 Oct 2009). 9. Agrawal T, Vats V, Wallace L. Role of cervical dendritic cell subsets, co-stimulatory molecules, cytokine secretion profile and beta-estradiol in development of sequalae to Chlamydia trachomatis infection. BMC Reproduct Biol Endocrinol 2008;6:46. 10. Silins I, Ryd W, Strand A, et al. Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer 2005;116:110e15. 11. Samoff E, Koumans EH, Markowitz LE, et al. Association of Chlamydia trachomatis with persistence of high-risk types of human papillomavirus in a cohort of female adolescents. Am J Epidemiol 2005;162:668e75. 12. Velicer C, Zhu X, Vuocolo S, et al. Prevalence and incidence of HPV genital infection in women. Sex Transm Dis 2009;36:696e703. 13. Shew ML, Fortenberry JD, Tu W, et al. Association of condom use, sexual behaviors, and sexually transmitted infections with the duration of genital human papillomavirus infection among adolescent women. Arch Pediatr Adolesc Med 2006;160:151e6. 14. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928e43. 15. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915e27. 16. International Patent Numbers WO 2003/019143 A2, WO 2006/116276 A2 and WO 2006/116303 A2. http://www.wipo.int/portal/index.html.en. (accessed 5 May 2010). 17. Villa LL, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271e8. 18. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006;107:18e27. 19. Li N, Franscheski S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011;128:927e35. 20. Cox DR. Regression models and life tables. J R Stat Soc Ser B Methodological 1972;34:187e220. 21. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272e8. 22. Lehtinen M, Dillner J, Knekt P, et al. Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study. Br Med J 1996;312:537e9. 23. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009;4:8.